P A Palmer
Overview
Explore the profile of P A Palmer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
264
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gore L, Holden S, Cohen R, Morrow M, Pierson A, OBryant C, et al.
Ann Oncol
. 2006 Sep;
17(11):1709-17.
PMID: 16980604
Background: To evaluate the toxicity and pharmacological and biological properties of the farnesyl protein transferase (FPTase) inhibitor, tipifarnib (R115777, ZARNESTRAtrade mark) and capecitabine administered for 14 days every 3 weeks....
2.
Rao S, Cunningham D, de Gramont A, Scheithauer W, Smakal M, Humblet Y, et al.
J Clin Oncol
. 2004 Oct;
22(19):3950-7.
PMID: 15459217
Purpose: To determine whether R115777 improves survival in patients with refractory advanced colorectal cancer (CRC) in a multicenter, double-blind, prospective randomized study. Patients And Methods: Three hundred sixty-eight patients were...
3.
Sparreboom A, Kehrer D, Mathijssen R, Xie R, de Jonge M, de Bruijn P, et al.
Br J Cancer
. 2004 Apr;
90(8):1508-15.
PMID: 15083177
The aims of this study were to determine the maximum-tolerated dose (MTD), toxicity profile, and pharmacokinetics of irinotecan given with oral R115777 (tipifarnib), a farnesyl protein transferase inhibitor. Patients were...
4.
Crul M, de Klerk G, Swart M, Vant Veer L, de Jong D, Boerrigter L, et al.
J Clin Oncol
. 2002 Jun;
20(11):2726-35.
PMID: 12039935
Purpose: To determine the maximum-tolerated dose, toxicities, and pharmacokinetics of R115777, a farnesyl transferase inhibitor, when administered continuously via the oral route. Patients And Methods: Patients with advanced solid malignancies...
5.
van Zuylen L, Sparreboom A, van der Gaast A, Nooter K, Eskens F, Brouwer E, et al.
Eur J Cancer
. 2002 May;
38(8):1090-9.
PMID: 12008197
Recently, a study of docetaxel in combination with the new orally administered P-glycoprotein (P-gp) inhibitor R101933 showed that this combination was feasible. However, due to the low oral bioavailability of...
6.
Crul M, de Klerk G, Swart M, Weiner L, Palmer P, Bol C, et al.
Eur J Drug Metab Pharmacokinet
. 2002 May;
27(1):61-5.
PMID: 11996329
R115777 (Zamestra) is a novel anticancer agent, currently undergoing phase III clinical testing. An open, cross-over trial was performed in 24 patients with solid tumors to compare the bioavailability of...
7.
van Zuylen L, Sparreboom A, van der Gaast A, van der Burg M, van Beurden V, Bol C, et al.
Clin Cancer Res
. 2000 Apr;
6(4):1365-71.
PMID: 10778964
This Phase I study was performed to assess the feasibility of combining docetaxel with the new P-glycoprotein inhibitor R101933 and to determine the dose limiting toxicity of this combination. Fifteen...
8.
Heys S, Eremin O, Ruggeri E, Pein F, Rainer H, Oskam R, et al.
Eur J Cancer
. 1995 Jan;
31A(1):19-25.
PMID: 7695972
135 patients with locally advanced or metastatic colorectal cancer were entered into a phase III trial evaluating the efficacy of chemoimmunotherapy [recombinant interleukin 2 (rIL2)/5-fluorouracil (5-FU) and leucovorin (LV)] versus...
9.
Mattijssen V, de Mulder P, de Graeff A, Hupperets P, Joosten F, Ruiter D, et al.
Ann Oncol
. 1994 Dec;
5(10):957-60.
PMID: 7696170
Background: An enhanced efficacy of local as compared to systemic administration of interleukin-2 (IL-2) has been demonstrated in several experimental tumors. We previously reported that guinea pigs with palpable tumors...
10.
Palmer P, Scharenberg J, von Blomberg B, Stam A, Meijer C, Roest G, et al.
Cancer Immunol Immunother
. 1994 Jul;
39(1):34-40.
PMID: 8044824
The toxicity of high-dose recombinant interleukin-2 (rIL-2) treatment limits its use in tumour therapies. This paper describes in vitro studies of whether a single, peak rIL-2 dose, followed by low...